Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01110720
Other study ID # AL-108-231
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received April 23, 2010
Last updated January 15, 2013
Start date October 2010
Est. completion date December 2012

Study information

Verified date January 2013
Source Allon Therapeutics
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationAustralia: Department of Health and Ageing Therapeutic Goods AdministrationCanada: Health CanadaFrance: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)Germany: Federal Institute for Drugs and Medical DevicesUnited Kingdom: Medicines and Healthcare Products Regulatory Agency
Study type Interventional

Clinical Trial Summary

The purpose of the study is to evaluate the safety and efficacy of davunetide for the treatment of Progressive Supranuclear Palsy.


Description:

A Phase 2/3,Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy


Recruitment information / eligibility

Status Completed
Enrollment 313
Est. completion date December 2012
Est. primary completion date November 2012
Accepts healthy volunteers No
Gender Both
Age group 41 Years to 85 Years
Eligibility Inclusion Criteria:

- Probable or possible PSP defined as:

- at least a 12-month history of postural instability or falls during the first 3 years that symptoms are present; and

- at screening, a decreased downward saccade velocity defined as observable eye movement (deviation from the "main sequence" linear relationship between saccade amplitude and saccade velocity) or, supranuclear ophthalmoplegia defined as 50% reduction in upward gaze or 30% reduction in downward gaze; and

- age at symptom onset of 40 to 85 years by history; and

- an akinetic-rigid syndrome with prominent axial rigidity.

- Aged 41 to 85 years at the time of screening.

- Judged by investigator to be able to comply with neuropsychological evaluation at baseline and throughout the study.

- Must have reliable caregiver accompany subject to all study visits. Caregiver must read, understand, and speak local language fluently to ensure comprehension of informed consent form and informant-based assessments of subject. Caregiver must also have frequent contact with subject (at least 3 hours per week at one time or at different times) and be willing to monitor study medication compliance and the subject's health and concomitant medications throughout the study.

- Modified Hachinski score = 3 (Appendix 7). This modified Hachinski will not include the focal neurological signs, symptoms or pseudobulbar affect questions, given the prominence of all 3 in PSP.

- Score = 15 on the mini-mental state examination (MMSE) at screening (Visit 1).

- Written informed consent provided by subject (or legally-appointed representative, as appropriate) and caregiver (if not the legally-appointed representative) who are both fluent local language speakers.

- Subject resides outside a skilled nursing facility or dementia care facility at the time of screening, and admission to such a facility is not planned. Residence in an assisted living facility is allowed.

- If the subject is receiving levodopa/carbidopa, levodopa/benserazide, a dopamine agonist, catechol-o-methyltransferase (COMT) inhibitor, or other Parkinson's medication,with teh exception of Azilect(rasagiline), the dose must have been stable for at least 60 days prior to the screening visit (Visit 1) and must remain stable for the duration of the study. No such medication can be initiated during the study. Subjects receiving rasagiline or CoQ10 must be on a stable dose for at least 90 days prior to the screening visit.

- Able to tolerate the MRI scan during screening with either no sedation or low dose lorazepam.

- Able to ambulate independently or with assistance defined as the ability to take at least 5 steps with a walker (guarding is allowed provided there is no contact) or the ability to take at least 5 steps with the assistance of another person who can only have contact with one upper extremity.

- Presence of symptoms for less than 5 years or the presence of symptoms for more than 5 years with a PSPRS baseline score = 40.

- Stable on all other chronic medications for at least 30 days prior to the screening visit (Visit 1).

Exclusion Criteria:

- Insufficient fluency in local language to complete neuropsychological and functional assessments.

- A diagnosis of Amyotrophic Lateral Sclerosis or other motor neuron disease.

- Any of the following:

- Abrupt onset of symptoms defined in inclusion criteria 1 associated with ictal events,

- Head trauma related to onset of symptoms defined in inclusion criteria 1,

- Severe amnesia within 6 months of the symptoms defined in inclusion criteria 1,

- Cerebellar ataxia,

- Choreoathetosis,

- Early, symptomatic autonomic dysfunction; or

- Tremor while at rest.

- Presence of other significant neurological or psychiatric disorders including (but not limited to) Alzheimer's disease; dementia with Lewy bodies; prion disease; Parkinson's disease (which has not subsequently been revised to PSP); any psychotic disorder; severe bipolar or unipolar depression; seizure disorder; tumor or other space-occupying lesion; or history of stroke or head injury with loss of consciousness for at least 15 minutes within the past 20 years.

- Within 4 weeks of screening or during the course of the study, concurrent treatment with memantine; acetylcholinesterase inhibitors; antipsychotic agents (other than quetiapine) or mood stabilizers (e.g., valproate, lithium); or benzodiazepines (except as below).

- Low dose lorazepam (not more than 2 mg) may be used for sedation prior to MRI scans for those subjects requiring sedation. Neuropsychological testing may not be performed after lorazepam administration.

- Subjects who take short acting benzodiazepines (only temazepam or zolpidem are allowed) for sleep may continue to do so if they have been on a stable dose for 30 days prior to screening.

- Clonazepam may be used for treatment of dystonia or painful rigidity associated with PSP if the dose has been stable for 90 days prior to screening and is not expected to change during the course of the study.

- Treatment with lithium, methylene blue, tramiprosate, ketone bodies, latrepirdine, or any putative disease-modifying agent directed at tau within 90 days of screening.

- A history of alcohol or substance abuse within 1 year prior to screening and deemed to be clinically significant by the site investigator.

- Any malignancy (other than non-metastatic dermatological conditions) within 5 years of the screening visit (Visit 1) or current clinically significant hematological, endocrine, cardiovascular, renal, hepatic, gastrointestinal, or neurological disease. For the non-cancer conditions, if the condition has been stable for at least one year before the screening visit and is judged by the site investigator not to interfere with the subject's participation in the study, the subject may be included.

- Clinically significant laboratory abnormalities at screening, including creatinine = 2.5 mg/dL, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) = 3 times the upper limit of the normal reference range, vitamin B12 below the laboratory normal reference range, or thyroid stimulating hormone TSH above laboratory normal reference range.

- The systolic blood pressure measurement is > 190 or < 85 mm Hg. The diastolic blood pressure measurement is > 105 or < 50 mm Hg at screening.

- Abnormal ECG tracing at screening and judged to be clinically significant by the site investigator.

- Treatment with any investigational drugs or device within 90 days of screening.

- Known history of serum or plasma progranulin level less than one standard deviation below the normal subject mean for the laboratory performing the assay.

- Known presence of known disease-associated mutation in TDP-43, PGRN, CHMPB2, or VCP genes or any other frontotemporal lobar degeneration (FTLD) causative genes not associated with underlying tau pathology (e.g., Chromosome 9 associated FTD).

- History of deep brain stimulator (DBS) surgery other than sham surgery for DBS clinical trial.

- History of early, prominent rapid eye movement (REM) sleep behavior disorder.

- Women who are pregnant or lactating and women of childbearing potential who are not using at least two different forms of medically recognized and highly effective methods of birth control, resulting in a low failure rate when used consistently and correctly such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomised partner.

- An employee or relative of an employee of the Sponsor, a clinical site, or Contract Research Organization participating in the study.

- Significant anatomical nasal abnormality (e.g., septal deviation obstructing airflow to at least one nostril or septal perforation) or history of nasal turbinate surgery.

- History of a clinically significant medical condition that would interfere with the subject's ability to comply with study instructions, would place the subject at increased risk, or might confound the interpretation of the study results.

- Contraindication to MRI examination for any reason (e.g., severe claustrophobia, ferromagnetic metal in body).

- Structural abnormality on MRI that precludes diagnosis of PSP, such as cortical infarct in brain region that might account for subject's symptoms.

- In subjects receiving anti-Parkinson's Disease medication at the time of screening, in the opinion of the investigator substantial worsening of motor signs or symptoms compared with normal functioning following overnight withdrawal of the anti-Parkinson medication.

- Known hypersensitivity to davunetide or any ingredient of the formulation.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Drug:
Davunetide
Davunetide Nasal Spray 30 mg BID IN 52 weeks
Placebo
Placebo Nasal Spray BID IN 52 weeks

Locations

Country Name City State
Australia The Alfred Hospital Melbourne Victoria
Canada London Sciences Health Center University Hospital London Ontario
Canada CHUM-Notre Dame Hospital Unité de Troubles du Mouvement Montreal Quebec
Canada McGill University Health Centre - Montreal General Hospital Montreal Quebec
Canada Parkinson's Disease & Movement Disorders Clinic Ottawa Ontario
Canada Toronto Western Hospital University Health Network Toronto Ontario
France Limoges University Hospital Limoges
France Hopital Timone Marseille
France Hôpitaux de Paris Paris
Germany Humboldt University Charité Berlin
Germany Neurologisch Klinik der Ruhr-Universität im St. Josef-Hospital Bochum
Germany Universitätsklinikum Carl Carus an der Technischen Universität Dresden
Germany Paracelsus-Elena Klinik Kassel
Germany Philipps Universität Marburg Marburg
Germany Klinikum Großhadern München
Germany Universität Rostock Zentrum für Nervenheilkunde und Poliklinik Rostock
Germany Universitäts- und Rehabilitationskliniken Ulm Ulm
United Kingdom Princess Royal Hospital Haywards Heath
United Kingdom Clinical Ageing Research Unit (CARU) Newcastle University Newcastle
United Kingdom Greater Manchester Neuroscience Centre Salford
United States University of Michigan Medical Center Ann Arbor Michigan
United States John Hopkins Hospital Baltimore Maryland
United States University of Alabama - Birmingham Birmingham Alabama
United States Parkinson's Disease and Movement Disorders Center of Boca Raton Boca Raton Florida
United States Massachusetts General Hospital Boston Massachusetts
United States Lahey Clinic Burlington Massachusetts
United States Univeristy of North Carolina Department of Neurology Chapel Hill North Carolina
United States University of Chicago Medical Center Chicago Illinois
United States University of Texas Southwestern Medical Center Dallas Texas
United States Colorado Neurological Institute - Rocky Mountain Movement Disorders Ctr, PC Englewood Colorado
United States Baylor College of Medicine Houston Texas
United States Mayo Clinic, Florida Jacksonville Florida
United States University of Kansas Medical Center Parkinson Disease & Movement Disorders Center Kansas City Kansas
United States David Geffen School of Medicine - UCLA Los Angeles California
United States USC Keck School of Medicine Los Angeles California
United States University of Louisville Division of Movement Disorders Louisville Kentucky
United States University of Minnesota Department of Neuology Minneapolis Minnesota
United States UMDNJ - Robert Wood Johnson Medical Center New Brunswick New Jersey
United States Columbia University New York New York
United States University of Pennsylvania Philadelphia Pennsylvania
United States Muhammed Ali Parkinson Center and Movement Disorders Clinic Phoenix Arizona
United States Mayo Clinic, Rochester, MN Rochester Minnesota
United States University of Utah Center for Alzheimer's Care, Imaging &Research Salt Lake City Utah
United States UCSD/VA Neurology Service San Diego California
United States UCSF Memory and Aging Center San Francisco California
United States Mayo Clinic, AZ Scottsdale Arizona
United States University Hospitals Case Medical CenterNI Movement Disorders Center South Euclid Ohio
United States The Frances J. Zesiewicz Foundation for Parkinson's Disease at USF Tampa Florida

Sponsors (1)

Lead Sponsor Collaborator
Allon Therapeutics

Countries where clinical trial is conducted

United States,  Australia,  Canada,  France,  Germany,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy, as measured by change from baseline scores of the Progressive Supranuclear Palsy Rating Scale (PSPRS) at 52 weeks 52 weeks No
Primary Efficacy, as measured by the change from baseline of the Schwab and England Activities of Daily Living Scale (SEADL) at 52 weeks 52 weeks No
Primary Safety, as measured by reported AEs, electrocardiograms (ECG), nasal examinations and clinical laboratory measures 52 weeks Yes
Secondary Efficacy, as measured by the Clinical Global Impression of Change (CGI-C) at 52 weeks 52 weeks No
Secondary Brain atrophy, as measured by change from baseline of ventricular volumes measured by volumetric brain MRI at 52 weeks. 52 weeks No
See also
  Status Clinical Trial Phase
Completed NCT04096651 - Pathophysiology of Gait and Posture in Progressive Supranuclear Palsy N/A
Recruiting NCT02194816 - Modifiable Variables in Parkinsonism (MVP)
Completed NCT00703677 - A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration Phase 1/Phase 2
Completed NCT00382824 - Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP) N/A
Completed NCT04184063 - Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA) Phase 2
Recruiting NCT04706234 - Systematic Assessment of Laryngopharyngeal Function in Patients With MSA, PD, and 4repeat Tauopathies
Recruiting NCT04472130 - Neurodegenerative Diseases Registry
Recruiting NCT04139551 - Oxford Study of Quantification in Parkinsonism
Completed NCT02734485 - Deep TMS for the Treatment of Patients With Parkinson's Disease and Progressive Supranuclear Palsy N/A
Completed NCT01174771 - Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration N/A
Completed NCT00465790 - Research of Biomarkers in Parkinson Disease Phase 0
Completed NCT02460094 - Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy Phase 1
Active, not recruiting NCT04993768 - A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) Phase 2
Recruiting NCT03225144 - Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Completed NCT03058965 - Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain Early Phase 1
Recruiting NCT02605785 - A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy N/A
Completed NCT01353183 - Analysis of the Enteric Nervous System Using Colonic Biopsies N/A
Completed NCT00385710 - Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine) Phase 2
Recruiting NCT05260151 - Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases
Active, not recruiting NCT04658199 - A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy Phase 1